title: Serum autoantibodies against cytochrome P450 2E1 (CYP2E1) predict severity of necroinflammation of recurrent hepatitis C.
abstract: We previously reported that autoantibodies against cytochrome P4502E1 (CYP2E1) are frequent in patients with chronic hepatitis C. As autoimmune reactions are increasingly detected after orthotopic liver transplantation (OLT), this study investigates prevalence and significance of anti-CYP2E1 autoantibodies in 46 patients with post-OLT recurrent hepatitis C. IgG against recombinant human CYP2E1 above the control threshold was detected in 19 out 46 (41%) sera collected immediately before OLT and in 15 out 46 (33%) sera collected at the time of the 12 months follow-up liver biopsy. Although anti-CYP2E1 reactivity was not modified by OLT, the patients with persistently elevated anti-CYP2E1 IgG (n = 12; 26%) showed significantly higher prevalence of recurrent hepatitis with severe necroinflammation and fibrosis than those persistently negative or positive only either before or after OLT. Moreover, the probability of developing severe necroinflammation was significantly higher in persistently anti-CYP2E1-positive subjects. Multivariate regression and Cox analysis confirmed that the persistence of anti-CYP2E1 IgG, together with a history of acute cellular rejection and donor age >50 years, was an independent risk factor for developing recurrent hepatitis C with severe necroinflammation. We propose that autoimmune reactions involving CYP2E1 might contribute to hepatic damage in a subgroup of transplanted patients with recurrent hepatitis C.
authors.affiliation: First Division of Gastroenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena and University of Milan, Italy. crigamo@tin.it
authors.forename: C
authors.initials: C
authors.lastname: Rigamonti
authors.forename: M
authors.initials: M
authors.lastname: Vidali
authors.forename: M F
authors.initials: MF
authors.lastname: Donato
authors.forename: S
authors.initials: S
authors.lastname: Sutti
authors.forename: G
authors.initials: G
authors.lastname: Occhino
authors.forename: A
authors.initials: A
authors.lastname: Ivaldi
authors.forename: E
authors.initials: E
authors.lastname: Arosio
authors.forename: F
authors.initials: F
authors.lastname: Agnelli
authors.forename: G
authors.initials: G
authors.lastname: Rossi
authors.forename: M
authors.initials: M
authors.lastname: Colombo
authors.forename: E
authors.initials: E
authors.lastname: Albano
mesh_terms: D001323:Autoantibodies / Q000097:blood* / Q000276:immunology*; D019392:Cytochrome P-450 CYP2E1 / Q000276:immunology* / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000097:blood / Q000201:enzymology* / Q000276:immunology / Q000473:pathology*; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000276:immunology / Q000473:pathology; D008103:Liver Cirrhosis / Q000209:etiology / Q000473:pathology / Q000601:surgery; D008297:Male; D009336:Necrosis / Q000097:blood / Q000276:immunology / Q000473:pathology; D012008:Recurrence; D012307:Risk Factors
chemical_list: D001323:Autoantibodies; D019392:Cytochrome P-450 CYP2E1